Skip to main content

Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy

CBE ID
2764e
1.4 Project
Cardiovascular
Endorsed
Endorsement Status
Approval for Trial Use Removed
E&M Cycle
Spring 2023
Is Under Review
No
Next Planned Maintenance Review
Cardiovascular Spring 2023
1.3 Measure Description

Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) and a current or prior ejection fraction (EF) <40% who are self-identified Black or African Americans and receiving ACEI or ARB and Beta-blocker therapy who were prescribed a fixed-dose combination of hydralazine and isosorbide dinitrate seen for an office visit in the measurement period in the outpatient setting or at each hospital discharge

    • 1.14 Numerator

      Patients prescribed a fixed-dose combination of hydralazine and isosorbide dinitrate seen for an office visit in the measurement period in the outpatient setting or at each hospital discharge

    • 1.15 Denominator

      All patients aged 18 years and older with a diagnosis of heart failure with a current or prior EF <40% who are self-identified Black or African Americans and receiving ACEI or ARB and Beta-blocker therapy

    • Exclusions

      Denominator exclusions include:
      o Hypotension (severe or symptomatic)
      o Severe lupus erythematosus
      o Unstable angina
      o Peripheral neuritis
      o Patient actively taking Phosphodiesterase Type 5 (PDE5) Inhibitors

    • Most Recent Endorsement Activity
      Approval for Trial Use Removed Cardiovascular Spring 2023
      Initial Endorsement
      Last Updated
      Removal Date
    • Steward
      National Minority Quality Forum
      Steward Organization Email
      [email protected]
      Steward Organization Copyright

      This documentation contains proprietary information, and is protected by U.S. copyright. All rights reserved.

      These Performance Measures (Measures) and all related data specifications have been developed by NMQF.

      No part of this documentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, modifying, or recording, without the prior written permission of National Minority Quality Forum (NMQF). No part of this documentation may be translated to another program language without the prior written consent of NMQF. Unauthorized posting of NMQF documents to a non-NMQF website is prohibited. The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measure require a license agreement between the user and the NMQF. For information on reprint and linking permissions, please visit NMQF’s Terms of Use page (http://heartfailurequalityimprovementinitiative.com/terms-of-use/). Neither the NMQF, nor its members shall be responsible for any use of the Measures.

      © 2015 National Minority Quality Forum. All Rights Reserved.